Alyeska Investment Group L.P. reduced its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 52.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 87,744 shares of the company's stock after selling 97,119 shares during the quarter. Alyeska Investment Group L.P. owned 0.13% of Oruka Therapeutics worth $8,351,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of ORKA. Orion Capital Management LLC bought a new stake in Oruka Therapeutics during the second quarter worth about $91,000. Royal Bank of Canada grew its stake in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in Oruka Therapeutics in the 4th quarter valued at about $37,000. PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics in the 3rd quarter valued at about $39,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at approximately $67,000. Institutional investors own 56.44% of the company's stock.
Oruka Therapeutics Trading Up 1.6%
ORKA opened at $92.62 on Tuesday. The company's 50 day moving average is $94.75 and its 200-day moving average is $68.17. Oruka Therapeutics, Inc. has a 1-year low of $14.61 and a 1-year high of $115.51. The company has a market cap of $6.13 billion, a P/E ratio of -45.63 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.33 EPS for the current year.
Insider Transactions at Oruka Therapeutics
In other Oruka Therapeutics news, Director Carl Dambkowski sold 12,583 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the sale, the director directly owned 38,743 shares of the company's stock, valued at $2,716,271.73. The trade was a 24.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the sale, the senior vice president owned 15,312 shares of the company's stock, valued at $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 83,116 shares of company stock worth $6,636,533. Insiders own 23.49% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently weighed in on ORKA. BTIG Research reaffirmed a "buy" rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. UBS Group boosted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a research report on Wednesday, July 1st. Wall Street Zen downgraded shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Piper Sandler restated an "overweight" rating and set a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $134.30.
View Our Latest Stock Analysis on ORKA
Oruka Therapeutics Company Profile
(
Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Further Reading
Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
